SHINE a light: frontline ibrutinib for MCL was written by Killock, David. And the article was included in Nature Reviews Clinical Oncology in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:
Many patients with mantle cell lymphoma (MCL) are ineligible for intensive therapy, including allogeneic stem cell transplantation (ASCT), and are instead treated with bendamustine and rituximab (BR). SHINE involved 523 patients aged â?5 with stage II-IV MCL for whom ASCT was not planned. These results demonstrate the efficacy of combining ibrutinib with BR in patients with MCL. However, the optimal sequencing of these therapies, as well as other approved treatments, remains unclear. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem